Pharmaceutical filing citing British Journal of Dermatology paper — Traws Pharma, 2025-06-03
Traws PharmaTraws PharmaNASDAQ TRAW
Filings SEC · Quote Yahoo cited a paper published in the British Journal of Dermatology as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper in the press release like this
When a U.S. listed company has something to inform shareholders, it submits a current report to the Securities and Exchange Commission, called 8-K. The item numbers of the document submitted by Traws Pharma on 2025-06-03 were 7.01 Reg FD Public · 8.01 Other Events · 9.01 Financial Statements·Attachments. The company cited a paper published in British Journal of Dermatology in the attached press release. The sentence citing the paper, copied verbatim from the original, is as follows.
The paper, published in the British Journal of Dermatology 1 , details the first clinical trial of any experimental cancer therapeutic in this rare and complicated monogenic disease. The results indicated an overall response rate of 80%, with complete responses in 50% of evaluable patients.
What readers should first look at is where the company placed the paper in the press release. Next, they should determine whether the paper supports the entire company claim or only a part of it. To answer the latter question, one must read the full paper. This article, which reads only the abstract, cannot answer it.
The scope of the paper mentioned in the abstract is up to here.
The paper title is Efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa-associated advanced/metastatic cutaneous squamous cell carcinoma and it was published in British Journal of Dermatology on 2025-05-23. The authors' affiliations are Paracelsus Medical University · EB House Austria · Thomas Jefferson University · Sidney Kimmel Cancer Center. The summary published at the beginning of the paper is called abstract. What this article has read is only up to there. This paragraph was rewritten by a person after filtering a draft written by a machine reading the abstract through numerical comparison, so it is of a different grade from a full-text reading and a definitive judgment.
This is a phase 2 trial of the anticancer drug Rigosertib in patients with aggressive skin cancer arising from autosomal recessive dystrophic epidermolysis bullosa, a genetic disorder causing easy skin peeling. Five patients who did not respond to standard treatment in Europe and the United States participated, choosing either an oral drug or an injection and being monitored for one year with photographs, biopsies, and PET/CT scans. Tumor size decreased within tolerable toxicity, and two patients showed complete response within six months. With only five patients in a single-arm trial, the sample size is too small to assess the magnitude of the effect.
The unaddressed issues remain in the full text and appendices. This article leaves gaps as gaps. Readers are to determine which sentence in the abstract corresponds to the cited excerpt by comparing the two citations above.
One month later, the stock price was in the bottom quarter.
The remaining return after subtracting the portion attributable to market movement is called excess return. Dates are counted in trading days, the days when the stock market is open. In calendar terms, 20 trading days are approximately one month. The excess return for the day of the filing and the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| 5 trading days before the filing | +6.6% | The extent of movement before the filing |
| On the filing date | +30.3% | On the filing date or the first trading day thereafter |
| Cumulative over +1 to +5 trading days | +29.4% | One week |
| Cumulative over +1 to +20 trading days | −27.4% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of -27.4% in this case is within the bottom quarter, at the 15% position from the bottom among 142 samples.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | Median | Top 25% | Top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −6.9% | +5.5% | +19.5% | −27.4% |
Half of the sample falls between the two central marks on the chart. One checks the chart to see whether this case lies within or outside the range. The sample collects cases where U.S.-listed companies cited papers in 8-K filings over the past ten years. The company itself is excluded from the sample. The numbers listed here are historical facts, not rules applicable to future cases.
There are two additional cases where the same company cited papers in 8-K filings, and they are included in the table below.
| Disclosure date | Journal of the cited paper | Excess return over one month |
|---|---|---|
| 2025-05-27 | New England Journal of Medicine | +5.5% |
| 2025-06-30 | New England Journal of Medicine | +0.1% |
Documents issued by the company after the disclosure
Only item numbers are listed for the three 8-K filings issued by the company after the disclosure date. In 8-K filings without titles, item numbers indicate the type of content. Whether it was an earnings announcement or a contract can be identified by the item number. The specific event is read in the original text of each link.
- 2025-06-30 8-K Items 7.01, 8.01, 9.01 — Reg FD disclosure · Other events · Financial statements and exhibits
- 2025-07-03 8-K Item 5.02 — Changes in Directors and Executive Officers
- 2025-08-14 8-K Items 2.02,7.01,9.01 — Earnings announcement · Reg FD disclosure · Financial statements and exhibits
What This Article Does Not Answer
This article, which reads only the abstract, cannot answer what the paper reviewed, how it was done, or what it showed. How many times the paper cited by the company has been cited afterward can be verified again through the OpenAlexOpenAlex
Data source · Website citation count. What will be seen next is whether the company's next 8-K again cites the same paper.
Glossary
- 8-K
- A voluntary report submitted to the U.S. Securities and Exchange Commission when a listed company has something to inform shareholders. Categories are indicated by item numbers such as earnings, contracts, and changes in officers. All events in this article come from this document.
- Excess return
- The remainder obtained by subtracting the market's overall return from the stock's return. It is used to observe the company's unique movement after removing the portion attributable to the market's collective rise or fall.
- Trading day
- A date counting only the days the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to approximately one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom within it is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details or limitations of the method.